|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 601 13th St., NW |
Address2 |
|
City | Washington |
State | DC |
Zip Code | 20005-2000 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 46676-12
|
||||||||
|
6. House ID# 395790000
|
TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: AMY E. MODLIN |
Date | 7/19/2023 10:47:49 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
affordability; COVID commercialization; Affordable Care Act; Telehealth extending flexibilities; Youth Mental Health - timing of legislation
introduction, school-based solutions; Health Equity; Site Neutrality Hospital Billing; Appropriations; Labor HHS Funding; Health Savings Accounts; mployee Retirement Income Security Act; Prior Authorization; Transparency in coverage; Surprise Billing; OPM Federal Employee Health Benefits rogram; Association Health Plans (AHPs)
S. 1001 Telehealth Expansion Act of 2023 o amend the Internal Revenue Code of 1986 to permanently extend the exemption for telehealth services from certain high deductible health plan les.
Sponsor: Sen. Daines, Steve IR-MT]
H.R. 485 - Protecting Health Care for All Patients Act of 2023 o amend title XI of the Social Security Act to prohibit the use of quality-adjusted life years and similar measures in coverage and payment eterminations under Federal health care programs. Sponsor: Rep. Cathy McMorris Rodgers (R-WA-05)
S.2016 - CONNECT for Health Act of 2023 o amend title XVIII of the Social Security Act to expand access to telehealth services, and for other purposes.
Sponsor: Sen. Schatz, Brian CD-HI]
H.R. 3561, The Patient Act of 2023 o promote hospital and insurer price transparency, and for other purposes.
Sponsor: Rep. McMorris Rodgers, Cathy [R-WA-5]
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Amy |
Modlin |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicaid same-day billing; Provider Directories; RADV Rule & Rate Notice; Medicare Advantage Advance Rate Notice and Prior Authorization Legislation; Medicaid Redeterminations; Medicare Wage Index Proposal; Draft Duals legislation; Medicaid work requirements; IRA Implementation
S.1038/H.R.1613 - Drug Price Transparency in Medicaid Act of 2023
Sponsor: Sen. Welch, Peter CD-VT]; Sponsor: Rep. Carter, Earl L. "Buddy" [R-GA-I] - To amend title XIX of the Social Security Act to improve ransparency and prevent the use of abusive spread pricing and related practices in the Medicaid program.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Amy |
Modlin |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Insulin Out of Pocket Charges; Finance PBNM Framework Proposals;
S. 150 - Affordable Prescriptions for Patients Act of 2023 bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
Sponsor: Sen. John Cornyn (R-TX)
S. 127 - Pharmacy Benefit Manager Transparency Act of 2023 bill to prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services or prescription drugs, and for other purposes.
Sponsor: Sen. Maria Cantwell (D-WA)
S. 1067 - Ensuring Timely Access to Generics Act of 2023 o amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions.
Sponsor: Sen. Shaheen, Jeanne [D-NH]
S. 1114 - Expanding Access to Low-Cost Generics Act of 2023 o amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period.
Sponsor: Sen. Smith, Tina [D-MN]
S. 1269 - INSULIN Act of 2023 o reduce the price of insulin and provide for patient protections with respect to the cost of insulin.
Sponsor: Sen. Shaheen, Jeanne [D-NH]
S. 1339 - Pharmacy Benefit Manager Reform Act o provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health nsurance coverage.
Sponsor: Sen. Sanders, Bernard [I-VT]
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Amy |
Modlin |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |